<clinical_study>
<study_id>
<org_name>
  Genzyme
</org_name>
<org_full_name>
  Genzyme
</org_full_name>
<org_study_id>
  AGLU02704
</org_study_id>
<secondary_id>
<id>
  2005-002759-42
</id>
<id_type>
  EudraCT Number
</id_type>
</secondary_id>
<nct_id>
  NCT00158600
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
A  Placebo-Controlled  Study  of  Safety  and  Effectiveness  of  Myozyme  (Alglucosidase Alfa) in  Patients  With  Late-Onset  Pompe  Disease  
</textblock>
</brief_title>
<official_title>
<textblock>
  Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Genzyme
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Medical Monitor
</name_title>
<organization>
  Genzyme Corporation
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<regulatory_authority>
  European Union: European Medicines Agency
</regulatory_authority>
<regulatory_authority>
  France: Afssaps - French Health Products Safety Agency
</regulatory_authority>
<regulatory_authority>
Netherlands:   College ter Beoordeling van Geneesmiddelen Medicines Evaluation Board (CBGMEB) 
</regulatory_authority>
<has_dmc>
  Yes
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
Pompe  disease  (also  known  as  glycogen  storage  disease  Type  II)  is  caused  by  a  deficiency  of  a  critical  enzyme  in  the  body  called  acid  alpha-glucosidase  (GAA).  Normally,  GAA  is  used  by  the  body&apos;s  cells  to  break  down  glycogen  (a  stored  form  of  sugar)  within  specialized  structures  called  lysosomes.  In  patients  with  Pompe  disease,  an  excessive  amount  of  glycogen  accumulates  and  is  stored  in  various  tissues,  especially  heart  and  skeletal  muscle,  which  prevents  their  normal  function.  The  overall  objective  is  to  evaluate  the  safety,  efficacy,  and  pharmacokinetics  (PK)  of   alglucosidase alfa treatment  in  patients  with  late-onset  Pompe  disease  as  compared  to  placebo.  
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
2010-06 
</date>
</status_block>
<start_date>
<date>
  2005-09
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
2007-09 
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2007-09
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  Summary of Patients Reporting Treatment-Emergent Adverse Events
</measure>
<time_frame>
  weeks 0-78
</time_frame>
<description>
<textblock>
  Overall safety summary of patients experiencing Adverse Events (AEs),
  Serious Adverse Events (SAEs), treatment-related AEs, and Infusion Associated Reactions (IARs).  Summary is based on Treatment-emergent AEs (TEAEs), defined as AEs that occurred following the initiation of study treatment, i.e., alglucosidase alfa or placebo.
</textblock>
</description>
<safety_issue>
  Yes
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
  Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline
</measure>
<time_frame>
  weeks 0, 78
</time_frame>
<description>
<textblock>
  Mean distance walked gives an indication of functional endurance.  The greater the distance, the greater the endurance.  Mean values of distance walked in a six-minute walk test are offered for baseline, week 78 (or last available observation), and the mean change from baseline (at week 78 or last available post-baseline observation).
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
  Percent of Predicted Forced Vital Capacity (FVC)
</measure>
<time_frame>
  weeks 0, 78
</time_frame>
<description>
<textblock>
  Forced vital capacity is a standard pulmonary function test used to quantify respiratory muscle weakness. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
  Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)
</measure>
<time_frame>
 weeks  0, 12 and 52 
</time_frame>
<description>
<textblock>
  Area under the plasma concentration versus time curve from time zero (pre-dose) to 16 hours after the end of infusion.  Blood sample time points were 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).  Pooled figures combine the values for the three timeframes.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
 Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax) 
</measure>
<time_frame>
 weeks  0, 12, 52 
</time_frame>
<description>
<textblock>
  Maximum plasma concentration observed in blood samples taken at the following  time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).  Pooled figures combine the values for the three timeframes.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
 Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax) 
</measure>
<time_frame>
 weeks  0, 12, 52 
</time_frame>
<description>
<textblock>
  Time to maximum plasma concentration observed in blood samples taken at the following  time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).  Pooled figures combine the values for the three timeframes.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
 Percent Predicted Proximal Muscle Strength of         the  Lower Limbs as  Measured by  Quantitative  Muscle  Testing  (QMT) 
</measure>
<time_frame>
 weeks  0, 78 
</time_frame>
<description>
<textblock>
  Quantitative muscle testing (QMT) is a standardized system to measure muscle force production during maximal voluntary isometric contraction. QMT data were collected directly from sensors into laptop computers. Predicted normal values for QMT are based on a formula using sex, age and body mass index of a person, and is an estimate of healthy muscle force. Percent of predicted QMT = (observed value)/(predicted value) * 100%. The QMT Leg Score is the average of the bilateral means for percent predicted knee flexors and extensors. A value of 100% indicates &apos;normal&apos; muscle strength.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
 Health-related Quality of   Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey 
</measure>
<time_frame>
 weeks  0, 78 
</time_frame>
<description>
<textblock>
  The Medical Outcomes Study Short Form (MOS SF)-36 questionnaire consists of 36 items grouped into 8 domains designed to assess generic health-related quality of life in healthy and ill adult populations. Physical Component Scores (PCS) report the four domains of physical functioning, role-physical, bodily pain, and general health. Higher scores are associated with better quality of life. All questions are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible.  The PCS scores are reported.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  90
</enrollment>
<condition>
Pompe  Disease  (Late-onset) 
</condition>
<condition>
  Glycogen Storage Disease Type II (GSD-II)
</condition>
<condition>
  Acid Maltase Deficiency Disease
</condition>
<condition>
  Glycogenosis 2
</condition>
<arm_group>
<arm_group_label>
 alglucosidase alfa 
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Placebo 
</arm_group_label>
<arm_type>
  Placebo Comparator
</arm_type>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
Biological/Vaccine 
</intervent_type>
<primary_name>
 alglucosidase alfa 
</primary_name>
<description>
<textblock>
IV  infusion  of  20mg/kg;  qow  for 78 weeks. 
</textblock>
</description>
<arm_group_label>
 alglucosidase alfa 
</arm_group_label>
<other_name>
  Myozyme
</other_name>
<other_name>
  alglucosidase alfa
</other_name>
<other_name>
  Lumizyme
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Placebo
</primary_name>
<description>
<textblock>
Placebo   Comparator; qow for 78 weeks. 
</textblock>
</description>
<arm_group_label>
Placebo 
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
-  Patient must  provide  signed,  informed  consent  prior  to  performing  any  study-related  procedures.  
-  Patient must  have  a  diagnosis  of  Pompe  disease  based  on  deficient  endogenous  GAA  activity  in  cultured  skin  fibroblasts  of  less  than  or  equal  to  40%  of  the  normal  mean  of  the  testing  laboratory  and  2  confirmed  GAA  gene  mutations;  
-  Patient must  be  greater  than  or  equal  to  8  years  of  age  at  the  time  of  enrollment;  
-  Patient must  be  able  to  ambulate  40  meters  (approximately  130  feet)  in  6  minutes  on  each      test performed  on  two consecutive days (use  of  assistive  devices  such  as  a  walker,  cane,  or  crutches,  is  permitted);  
-  Patient must  have  an  FVC  of  greater  than  or  equal  to  30%  and  &lt;  80%  predicted  in  the  upright  position;  
-  Patient must  have  a  postural  drop  in  FVC  (liters)  of  at  least  10%  from  the  upright  to  the  supine  position;  
-  Patient must  have  proximal  muscle  weakness  in  the  lower  limbs  based  on  unilateral  QMT  of  the  knee  extensors  defined  as  &lt;  80%  of  the  predicted  value  based  on  age,  gender  and  body  size  
-  Patient must  be  able  to  tolerate  pulmonary  function  testing  (PFT)  and  muscle  testing  in  the  supine  position;  
-  Patient must  have  testable  muscle  in  bilateral  knee  flexors  and  knee  extensors,  and  testable  muscle  in  bilateral  elbow  flexors  and  elbow  extensors;  
-  Patient must  be  able  to  provide  reproducible  muscle  and  pulmonary  function  test  results;  
-  Patient (and  patient&apos;s  legal  guardian  if  patient  is  &lt;  18  years  of  age)  must  have  the  ability  to  comply  with  the  clinical  protocol;  
    - A female patient of childbearing potential must have a negative pregnancy test (urine) at Baseline. Note: All female patients of childbearing potential and sexually mature males must use a medically accepted method of contraception throughout the study.
 
 
  Exclusion Criteria:
-  Patient requires  the  use  of  invasive  ventilatory  support;  
-  Patient requires  the  use  of  noninvasive  ventilatory  support  while  awake  and  in  an  upright  position;  
-  Patient has  received  enzyme  replacement  therapy  with  GAA  from  any  source;  
-  Patient has  used  an  investigational  product  within  30  days  prior  to  study  enrollment,  or  is  currently  enrolled  in  another  study  which  involves  clinical  evaluations,  unless  prior  approval  is  given  by  Genzyme;  
-  Patient has  a  major  congenital  anomaly,  medical  condition,  serious  intercurrent  illness,  or  other  extenuating  circumstance  that,  in  the  opinion  of  the  investigator,  may  significantly  interfere  with  study  compliance,  including  all  prescribed  evaluations  and  follow-up  activities;  
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  8 Years
</minimum_age>
<maximum_age>
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Medical Monitor
</name>
<affiliation>
<agency>
  Genzyme Corporation
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Medical Information
</name>
<phone>
  800-745-4447
</phone>
<phone_ext>
</phone_ext>
<email>
  medinfo@genzyme.com
</email>
</contact>
<contact>
<name>
  Medical Information
</name>
<phone>
  617-252-7832
</phone>
<phone_ext>
</phone_ext>
<email>
  medinfo@genzyme.com
</email>
</contact>
<location>
<facility>
<name>
  Tower Hematology Oncology Medical Group
</name>
<address>
<city>
  Beverly Hills
</city>
<state>
  California
</state>
<zip>
  90211
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Cheryl Elzinga
</name>
<phone>
  310-205-5708
</phone>
<phone_ext>
</phone_ext>
<email>
  ElzingaC@toweroncology.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Barry Rosenbloom, M.D.
</name>
</contact>
</location>
<location>
<facility>
<name>
  Children&apos;s National Medical Center
</name>
<address>
<city>
  Washington
</city>
<state>
  District of Columbia
</state>
<zip>
  20010
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Megan Coleman
</name>
<phone>
  202-884-4569
</phone>
<phone_ext>
</phone_ext>
<email>
  mcoleman@cnmcresearch.org
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Diana Escolar, M.D.
</name>
</contact>
</location>
<location>
<facility>
<name>
  Washington University Medical Center
</name>
<address>
<city>
  St. Louis
</city>
<state>
  Missouri
</state>
<zip>
  63110
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Charlie Wulf
</name>
<phone>
  314-362-6980
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<name>
  Julaine Florence, DPT
</name>
<phone>
  314-362-6983
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Alan Pestronk, M.D.
</name>
</contact>
</location>
<location>
<facility>
<name>
  Mount Sinai School of Medicine
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
  10029
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Jessica Cristian, M.S.
</name>
<phone>
  212-241-0495
</phone>
<phone_ext>
</phone_ext>
<email>
  Jessica.cristian@mssm.edu
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Melissa Wasserstein, M.D.
</name>
</contact>
</location>
<location>
<facility>
<name>
  University of Pittsburgh, Dept. of Neurology
</name>
<address>
<city>
  Pittsburgh
</city>
<state>
  Pennsylvania
</state>
<zip>
  15213
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Danielle Rowlands
</name>
<phone>
  412-383-7207
</phone>
<phone_ext>
</phone_ext>
<email>
  doerflerd@upmc.edu
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Paula Clemens, M.D.
</name>
</contact>
</location>
<location>
<facility>
<name>
  Groupe Hospitalier Pitie-Salpetriere
</name>
<address>
<city>
  Paris
</city>
<state>
</state>
<zip>
  75651
</zip>
<country>
  France
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Valerie Doppler, M.D.
</name>
<phone>
  +33 - (0) 1 42 16 58 73
</phone>
<phone_ext>
</phone_ext>
<email>
  valerie.doppler@psl.ap-hop-paris.fr
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Pascal Laforet, M.D.
</name>
</contact>
</location>
<location>
<facility>
<name>
  Erasmus Medical Centre Rotterdam
</name>
<address>
<city>
  Rotterdam
</city>
<state>
</state>
<zip>
  3015 GD
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Nadine van der Beek
</name>
<phone>
  +31-(0) 10-408-7821
</phone>
<phone_ext>
</phone_ext>
<email>
  n.beek@erasmusmc.nl
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  A.T. van de Ploeg, M.D.
</name>
</contact>
</location>
<location>
<facility>
<name>
  Sophia Children&apos;s Hospital, Erasmus MC
</name>
<address>
<city>
  Rotterdam
</city>
<state>
</state>
<zip>
  3000 CB
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Jacqueline Karelse-Hardon
</name>
<phone>
  31 (010) 4636003
</phone>
<phone_ext>
</phone_ext>
<email>
  J.Karelse@erasmusmc.nl
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Ans van der Ploeg, M.D.
</name>
</contact>
</location>
<keyword>
  Glycogen Storage Disease Type II
</keyword>
<keyword>
  GSD-II
</keyword>
<keyword>
  Pompe Disease
</keyword>
<initial_release_date>
  2005-09-08
</initial_release_date>
<last_release_date>
2010-06-24 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
  2010-06-24
</init_results_release_date>
<clinical_result>
<baseline>
<baselinemeasures>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  12.14
</dispersionspread>
<parametervalue>
  44.4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  12.37
</dispersionspread>
<parametervalue>
  45.3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<dispersionspread>
  11.63
</dispersionspread>
<parametervalue>
  42.6
</parametervalue>
</reportedvalue>
</reportedvalues>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Age at First Infusion
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
  Age Continuous
</title>
<unitofmeasure>
  years
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  45
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  26
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  19
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Female
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  45
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  34
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  11
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Male
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Gender, Male/Female
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Hispanic
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Asian
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Black or African American
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  84
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  57
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  27
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  White
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.2
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Unknown or not reported
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Race/Ethnicity, Customized
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
</baselinemeasures>
<baselinereportinggroups>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  60
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</baselinereportinggroup>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.2"
>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Placebo
</title>
</baselinereportinggroup>
</baselinereportinggroups>
<totalbaselinereportinggroup
 id="Baseline-TotalBaselineRptGroup"
>
<subjectsanalyzed>
  90
</subjectsanalyzed>
<title>
  Total
</title>
</totalbaselinereportinggroup>
</baseline>
<certainagreement>
<otherdetails>
<textblock>
  In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.
</textblock>
</otherdetails>
<pisponsoremployee>
  No
</pisponsoremployee>
<restrictiontype>
  OTHER
</restrictiontype>
<restrictiveagreement>
  Yes
</restrictiveagreement>
</certainagreement>
<lastupdatetimestamp>
  2010-06-24T09:09:01-04:00
</lastupdatetimestamp>
<outcomemeasures>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  60
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  30
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Patients with Any AEs
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  32
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  17
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Patients with Treatment-Related AEs
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  17
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  7
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Patients with Infusion-Associated Reactions
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  13
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  6
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Patients with SAEs
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  14
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  10
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Patients with Severe AEs
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Patients who Discontinued Due to AEs (incl death)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.2
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Patients who Died
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Overall safety summary of patients experiencing Adverse Events (AEs),
  Serious Adverse Events (SAEs), treatment-related AEs, and Infusion Associated Reactions (IARs).  Summary is based on Treatment-emergent AEs (TEAEs), defined as AEs that occurred following the initiation of study treatment, i.e., alglucosidase alfa or placebo.
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  weeks 0-78
</timeframe>
<title>
  Summary of Patients Reporting Treatment-Emergent Adverse Events
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  60
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.2"
>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Placebo
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  All patients who received any amount of study treatment comprise the safety population. Patients were considered, for safety analysis, to be in the treatment group of the treatment they actually received.
  Missing or invalid safety or resource utilization data were not replaced.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  Yes
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  126.69
</dispersionspread>
<parametervalue>
  332.20
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  132.29
</dispersionspread>
<parametervalue>
  317.93
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Distance Walked at Baseline
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  141.32
</dispersionspread>
<parametervalue>
  357.85
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  144.69
</dispersionspread>
<parametervalue>
  313.07
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Distance Walked at Last Available Observation
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  64.41
</dispersionspread>
<parametervalue>
  26.08
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  45.24
</dispersionspread>
<parametervalue>
  -4.87
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Change at Last Available Observation from Baseline
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Mean distance walked gives an indication of functional endurance.  The greater the distance, the greater the endurance.  Mean values of distance walked in a six-minute walk test are offered for baseline, week 78 (or last available observation), and the mean change from baseline (at week 78 or last available post-baseline observation).
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  weeks 0, 78
</timeframe>
<title>
  Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline
</title>
<unitofmeasure>
  meters
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
  2.07
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
  54.17
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
<textblock>
  The difference between alglucosidase alfa and placebo treatment groups in change in distance walked from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.
</textblock>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
  Difference
</othertypename>
<parametertype>
  Other
</parametertype>
<parametervalue>
  28.12
</parametervalue>
<pvalue>
  0.0347
</pvalue>
<pvaluecomment>
<textblock>
  The threshold for determining statistical significance is 0.05. A fixed testing sequence procedure was used to preserve an overall error rate of 5% for the co-primary efficacy endpoints by linking the test of FVC to the result of 6MWT.
</textblock>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  60
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.2"
>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Placebo
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intent-to-Treat (ITT) population.  Last observation carried forward.  The last available distance walked for one patient was the Baseline visit; therefore, this patient was excluded from the change from baseline calculation.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  14.44
</dispersionspread>
<parametervalue>
  55.43
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  15.66
</dispersionspread>
<parametervalue>
  53.00
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Baseline (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  16.30
</dispersionspread>
<parametervalue>
  56.71
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  14.88
</dispersionspread>
<parametervalue>
  50.70
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 78 (or last observation)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  5.55
</dispersionspread>
<parametervalue>
  1.25
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  4.33
</dispersionspread>
<parametervalue>
  -2.30
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Change at Week 78 from Baseline
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Forced vital capacity is a standard pulmonary function test used to quantify respiratory muscle weakness. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  weeks 0, 78
</timeframe>
<title>
  Percent of Predicted Forced Vital Capacity (FVC)
</title>
<unitofmeasure>
  percent predicted FVC
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
  1.03
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
  5.77
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
<textblock>
  The difference between alglucosidase alfa and placebo treatment groups in change in % predicted FVC from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.
</textblock>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
  Difference
</othertypename>
<parametertype>
  Other
</parametertype>
<parametervalue>
  3.40
</parametervalue>
<pvalue>
  0.0055
</pvalue>
<pvaluecomment>
<textblock>
  The threshold for determining statistical significance is 0.05. A fixed testing sequence procedure was used to preserve an overall error rate of 5% for the co-primary efficacy endpoints by linking the test of FVC to the result of 6MWT.
</textblock>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  60
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.2"
>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Placebo
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  ITT population.  Last observation carried forward.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  18.88
</dispersionspread>
<parametervalue>
  37.69
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  18.24
</dispersionspread>
<parametervalue>
  32.49
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Baseline (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  21.83
</dispersionspread>
<parametervalue>
  39.05
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  20.54
</dispersionspread>
<parametervalue>
  30.40
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 78 (or last available observation)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  9.88
</dispersionspread>
<parametervalue>
  1.22
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  5.11
</dispersionspread>
<parametervalue>
  -2.08
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Change at Week 78 from Baseline
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Quantitative muscle testing (QMT) is a standardized system to measure muscle force production during maximal voluntary isometric contraction. QMT data were collected directly from sensors into laptop computers. Predicted normal values for QMT are based on a formula using sex, age and body mass index of a person, and is an estimate of healthy muscle force. Percent of predicted QMT = (observed value)/(predicted value) * 100%. The QMT Leg Score is the average of the bilateral means for percent predicted knee flexors and extensors. A value of 100% indicates &apos;normal&apos; muscle strength.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  weeks 0, 78
</timeframe>
<title>
  Percent Predicted Proximal Muscle Strength of the Lower Limbs as Measured by Quantitative Muscle Testing (QMT)
</title>
<unitofmeasure>
  percent predicted QMT
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.4-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
  -0.73
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
  7.08
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
<textblock>
  The difference between alglucosidase alfa and placebo treatment groups in change in QMT from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.
</textblock>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
  Difference
</othertypename>
<parametertype>
  Other
</parametertype>
<parametervalue>
  3.18
</parametervalue>
<pvalue>
  0.1093
</pvalue>
<pvaluecomment>
<textblock>
  The threshold for determining statistical significance is 0.05.  No adjustment for multiple comparison was made for secondary efficacy endpoints.
</textblock>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  60
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.4-OutcomeRptGroup.2"
>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Placebo
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  ITT population.  Last observation carried forward.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  8.93
</dispersionspread>
<parametervalue>
  34.33
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  7.26
</dispersionspread>
<parametervalue>
  34.91
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  PCS at Baseline (week 0)
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  9.84
</dispersionspread>
<parametervalue>
  35.11
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  9.57
</dispersionspread>
<parametervalue>
  36.47
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  PCS at Week 78 (or last available observation)
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  The Medical Outcomes Study Short Form (MOS SF)-36 questionnaire consists of 36 items grouped into 8 domains designed to assess generic health-related quality of life in healthy and ill adult populations. Physical Component Scores (PCS) report the four domains of physical functioning, role-physical, bodily pain, and general health. Higher scores are associated with better quality of life. All questions are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible.  The PCS scores are reported.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  weeks 0, 78
</timeframe>
<title>
  Health-related Quality of Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey
</title>
<unitofmeasure>
  Units on a scale
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
<measureanalysis>
<outcomereportinggroups>
<outcomereportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.1
</outcomereportinggroupid>
<outcomereportinggroupid>
  OutcomeMeasure.5-OutcomeRptGroup.2
</outcomereportinggroupid>
</outcomereportinggroups>
<cilowerlimit>
  -3.83
</cilowerlimit>
<cinumsides>
</cinumsides>
<cipctvalue>
  95
</cipctvalue>
<ciupperlimit>
  3.09
</ciupperlimit>
<dispersiontype>
</dispersiontype>
<dispersionvalue>
</dispersionvalue>
<estimatecomment>
</estimatecomment>
<groupdescription>
<textblock>
  The difference between alglucosidase alfa and placebo treatment groups in change in PCS from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.
</textblock>
</groupdescription>
<noninferioritytestcomment>
</noninferioritytestcomment>
<othermethodname>
</othermethodname>
<othertypename>
  Difference
</othertypename>
<parametertype>
  Other
</parametertype>
<parametervalue>
  -0.37
</parametervalue>
<pvalue>
  0.8333
</pvalue>
<pvaluecomment>
<textblock>
  The threshold for determining statistical significance is 0.05.  No adjustment for multiple comparison was made for secondary efficacy endpoints.
</textblock>
</pvaluecomment>
<statisticalmethod>
  ANCOVA
</statisticalmethod>
<statisticaltestcomment>
</statisticaltestcomment>
<testednoninferiority>
  No
</testednoninferiority>
</measureanalysis>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  60
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.5-OutcomeRptGroup.2"
>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  30
</subjectsanalyzed>
<title>
  Placebo
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  ITT population.  Last observation carried forward.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  1139.85
</dispersionspread>
<parametervalue>
  2672.47
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 0
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  555.09
</dispersionspread>
<parametervalue>
  2386.76
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 12
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  999.97
</dispersionspread>
<parametervalue>
  2699.28
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 52
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.6-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  933.28
</dispersionspread>
<parametervalue>
  2586.17
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pooled
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Area under the plasma concentration versus time curve from time zero (pre-dose) to 16 hours after the end of infusion.  Blood sample time points were 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).  Pooled figures combine the values for the three timeframes.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  weeks 0, 12 and 52
</timeframe>
<title>
  Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)
</title>
<unitofmeasure>
  ug*h/mL
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.6-OutcomeRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  32
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  The subgroup of patients for whom pharmacokinetic samples were obtained was based on those study sites that could accommodate pharmacokinetic sampling needs.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  105585
</dispersionspread>
<parametervalue>
  385237
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 0
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  78620
</dispersionspread>
<parametervalue>
  349269
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 12
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  88203
</dispersionspread>
<parametervalue>
  369744
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 52
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  91721
</dispersionspread>
<parametervalue>
  368083
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pooled
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Maximum plasma concentration observed in blood samples taken at the following  time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).  Pooled figures combine the values for the three timeframes.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  weeks 0, 12, 52
</timeframe>
<title>
  Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax)
</title>
<unitofmeasure>
  ng/mL
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.7-OutcomeRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  32
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  The subgroup of patients for whom pharmacokinetic samples were obtained was based on those study sites that could accommodate pharmacokinetic sampling needs.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  0.33
</dispersionspread>
<parametervalue>
  3.62
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 0
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  0.28
</dispersionspread>
<parametervalue>
  3.62
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 12
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  0.31
</dispersionspread>
<parametervalue>
  3.64
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 52
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  0.30
</dispersionspread>
<parametervalue>
  3.63
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Pooled
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Time to maximum plasma concentration observed in blood samples taken at the following  time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion).  Pooled figures combine the values for the three timeframes.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  weeks 0, 12, 52
</timeframe>
<title>
  Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax)
</title>
<unitofmeasure>
  hours
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.8-OutcomeRptGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<subjectsanalyzed>
  32
</subjectsanalyzed>
<title>
  Alglucosidase Alfa
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  The subgroup of patients for whom pharmacokinetic samples were obtained was based on those study sites that could accommodate pharmacokinetic sampling needs.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
</outcomemeasure>
</outcomemeasures>
<participantflow>
<participantflowgroups>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<title>
  Alglucosidase Alfa
</title>
</flowgroup>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.2"
>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
<title>
  Placebo
</title>
</flowgroup>
</participantflowgroups>
<periods>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  55
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  26
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  unable to commit time to study
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Adverse Event
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  0
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Death
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<subjectsaffected>
  2
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Withdrawal by Subject
</reasontype>
</dropwithdrawreason>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  5
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
<otherdetail>
<numbernotcompleted>
  4
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  60
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.2
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  30
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Overall Study
</title>
</period>
</periods>
<preassignmentdescription>
<textblock>
  One hundred patients screened and 90 enrolled.
</textblock>
</preassignmentdescription>
<recruitmentdetails>
</recruitmentdetails>
</participantflow>
<pointofcontact>
<email>
</email>
<organizationname>
  Genzyme Corporation
</organizationname>
<phoneextension>
</phoneextension>
<phonenumber>
  800-745-4447
</phonenumber>
<title>
  Genzyme Medical Information
</title>
</pointofcontact>
<recordstatus>
  RELEASED
</recordstatus>
<reportedevents>
<assessmenttype>
</assessmenttype>
<frequencyreportingthreshold>
  0
</frequencyreportingthreshold>
<frequentadverseevents>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Anaemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Lymphadenopathy
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Macrocytosis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Normochromic normocytic anaemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Angina pectoris
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Bundle branch block left
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Bundle branch block right
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Coronary artery disease
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Palpitations
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Sinus tachycardia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tachycardia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tricuspid valve incompetence
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Auricular swelling
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Ear congestion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Ear discomfort
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Ear pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  20
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  27
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypoacusis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Presbyacusis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tinnitus
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tympanic membrane disorder
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tympanic membrane scarring
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Ear and labyrinth disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vertigo
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Altered visual depth perception
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Asthenopia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Cataract
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Conjunctivitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Diplopia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dry eye
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Eye irritation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Eye pruritus
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Lacrimation increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Photophobia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vision blurred
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Visual disturbance
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Eye disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vitreous floaters
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abdominal discomfort
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abdominal distension
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abdominal mass
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abdominal pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abdominal pain lower
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abdominal pain upper
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Constipation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dental caries
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  18
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  31
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Diarrhoea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Diverticulum
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dry mouth
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dyspepsia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dysphagia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Epigastric discomfort
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Flatulence
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Food poisoning
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Gastrointestinal disorder
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Gastrooesophageal reflux disease
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Glossodynia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Haematochezia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hiatus hernia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Inguinal hernia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Lip swelling
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  21
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Nausea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Oesophageal pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Oral mucosal blistering
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Oral pruritus
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Paraesthesia oral
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Retching
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Stomach discomfort
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Swollen tongue
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Toothache
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  16
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vomiting
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Application site vesicles
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Asthenia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Axillary pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Catheter related complication
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Catheter site pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Catheter site related reaction
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Chest discomfort
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Chest pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Chills
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Fatigue
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Feeling abnormal
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Feeling cold
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Feeling hot
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Feeling hot and cold
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Gait disturbance
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hangover
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Influenza like illness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Infusion site bruising
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Infusion site pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Infusion site paraesthesia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Infusion site reaction
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Injection site phlebitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Local swelling
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Malaise
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Non-cardiac chest pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  13
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Oedema peripheral
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pitting oedema
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Puncture site haemorrhage
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  16
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pyrexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Thirst
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vessel puncture site haematoma
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Immune system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypersensitivity
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Bronchitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Bronchopneumonia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Cellulitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Cystitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dermatophytosis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Eye infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Folliculitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Fungal infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Fungal skin infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Gastroenteritis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Gastroenteritis viral
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Gastrointestinal infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Genital infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Gingival infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Herpes simplex
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Herpes virus infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Influenza
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Kidney infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Laryngitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Localised infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Mucosal infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  25
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  16
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  41
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Nasopharyngitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Otitis media
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Postoperative wound infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rash pustular
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Respiratory tract infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rhinitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Sinusitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tinea pedis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tonsillitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tooth infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Upper respiratory tract infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Urinary tract infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vaginal infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Viral infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vulvovaginal mycotic infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Wound infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Accident
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Animal bite
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Arthropod bite
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Arthropod sting
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Back injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Contusion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Excoriation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  39
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  20
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  59
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Fall
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Femur fracture
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Foot fracture
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Humerus fracture
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Injury corneal
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Joint dislocation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Joint sprain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Laceration
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Ligament injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Limb crushing injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Limb injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Muscle strain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Periorbital haematoma
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Procedural pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Repetitive strain injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rib fracture
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Road traffic accident
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Skeletal injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Skin laceration
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tendon injury
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Thermal burn
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tooth fracture
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Traumatic ulcer
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vaccination complication
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Wound
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Alanine aminotransferase increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Aspartate aminotransferase increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood alkaline phosphatase increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood creatine phosphokinase MB increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood folate decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood glucose increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood parathyroid hormone increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood pressure increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood thyroid stimulating hormone increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood uric acid increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blood urine present
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Carbon dioxide increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Electrocardiogram QT corrected interval prolonged
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Eosinophil count increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Forced expiratory volume decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Glucose urine present
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Heart rate irregular
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  International normalised ratio decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Lymph node palpable
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Neutrophil count increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Oxygen saturation decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Protein total increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Protein urine present
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Specific gravity urine decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Urine ketone body present
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vitamin D decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Weight decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Weight increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  White blood cell count increased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Investigations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  White blood cells urine positive
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Decreased appetite
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Diabetes mellitus non-insulin-dependent
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hyperglycaemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypernatraemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypertriglyceridaemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypokalaemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  18
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  27
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Arthralgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  21
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Back pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Bone pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Bursitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Buttock pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Costochondritis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Exostosis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Flank pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Foot deformity
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Groin pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Joint range of motion decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Joint swelling
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Muscle atrophy
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Muscle contracture
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  20
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Muscle spasms
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Muscle tightness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Muscle twitching
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Muscular weakness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Musculoskeletal chest pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Musculoskeletal discomfort
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Musculoskeletal disorder
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Musculoskeletal pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Musculoskeletal stiffness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  17
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Myalgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Neck pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Nose deformity
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Osteopenia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Osteoporosis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  15
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  22
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pain in extremity
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Plantar fasciitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Scoliosis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Sensation of heaviness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Temporomandibular joint syndrome
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tendon pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tendonitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tenosynovitis stenosans
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Melanocytic naevus
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Areflexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Balance disorder
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Burning sensation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Carpal tunnel syndrome
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Disturbance in attention
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  14
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  20
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dizziness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dizziness postural
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dysgeusia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Facial palsy
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Head discomfort
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  24
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  15
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  39
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Headache
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hyperreflexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypoaesthesia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hyporeflexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Intercostal neuralgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Intracranial hypotension
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Lethargy
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Loss of consciousness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Migraine
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Nerve compression
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  10
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Paraesthesia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Poor quality sleep
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Sinus headache
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Somnolence
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Syncope vasovagal
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Tremor
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abnormal dreams
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Anxiety
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Depression
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Insomnia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Panic attack
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Psychiatric disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Stress
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Haematuria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Leukocyturia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Nephrolithiasis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pollakiuria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Proteinuria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pyuria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Urinary incontinence
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Urine flow decreased
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Renal and urinary disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Urine odour abnormal
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Breast pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Breast swelling
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Breast tenderness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dysmenorrhoea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Fibrocystic breast disease
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Genital pruritus female
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Menstrual discomfort
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Menstruation irregular
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Scrotal cyst
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vaginal haemorrhage
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Asthma
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Bronchospasm
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Cough
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dyspnoea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dyspnoea exertional
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Epistaxis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Increased bronchial secretion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Lung disorder
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Lung infiltration
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Nasal congestion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Paranasal sinus hypersecretion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  12
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  17
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pharyngolaryngeal pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Postnasal drip
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rales
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Respiratory distress
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Respiratory failure
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Respiratory tract congestion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rhinorrhoea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Sinus congestion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Sleep apnoea syndrome
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Sneezing
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Throat irritation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Throat tightness
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Wheezing
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Acne
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Blister
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Cold sweat
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Decubitus ulcer
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dermatitis contact
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Drug eruption
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Ecchymosis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Eczema
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Erythema
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Heat rash
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hyperhidrosis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Ingrowing nail
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Photosensitivity reaction
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pruritus
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  9
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rash
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rash macular
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rash maculo-papular
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rash papular
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Rash pruritic
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Skin burning sensation
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Skin lesion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Skin nodule
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Skin odour abnormal
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Skin warm
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Subcutaneous nodule
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Telangiectasia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Urticaria
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Aneurysm
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Diastolic hypotension
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  5
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Flushing
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Haematoma
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hot flush
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypertension
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypotension
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Phlebitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Raynaud&apos;s phenomenon
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Vasoconstriction
</term>
</frequentevent>
</frequentadverseevents>
<interventiongroups>
<interventiongroup
 id="ReportedEvents-InterventionGroup.1"
>
<description>
<textblock>
  Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
</textblock>
</description>
<numsubjectsfrequentevents>
  60
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  13
</numsubjectsseriousevents>
<partatriskfrequentevents>
  60
</partatriskfrequentevents>
<partatriskseriousevents>
  60
</partatriskseriousevents>
<title>
  Alglucosidase Alfa
</title>
</interventiongroup>
<interventiongroup
 id="ReportedEvents-InterventionGroup.2"
>
<description>
<textblock>
  Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
</textblock>
</description>
<numsubjectsfrequentevents>
  30
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  6
</numsubjectsseriousevents>
<partatriskfrequentevents>
  30
</partatriskfrequentevents>
<partatriskseriousevents>
  30
</partatriskseriousevents>
<title>
  Placebo
</title>
</interventiongroup>
<interventiongroup
 id="ReportedEvents-InterventionGroup.3"
>
<description>
</description>
<numsubjectsfrequentevents>
  90
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  19
</numsubjectsseriousevents>
<partatriskfrequentevents>
  90
</partatriskfrequentevents>
<partatriskseriousevents>
  90
</partatriskseriousevents>
<title>
  Overall
</title>
</interventiongroup>
</interventiongroups>
<notes>
<textblock>
  In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term,
  the individual has been included in the numerator (&quot;number of affected participants&quot;) of both adverse event tables.  Events are listed independent of relationship to treatment reported.
</textblock>
</notes>
<seriousadverseevents>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Coronary artery disease
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Cardiac disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Supraventricular tachycardia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abdominal pain
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Abdominal pain upper
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Chest discomfort
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Non-cardiac chest pain
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Immune system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Hypersensitivity
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Diverticulitis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Gastroenteritis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Pneumonia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Fall
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Humerus fracture
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Dehydration
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Flank pain
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Intervertebral disc protrusion
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Brain stem ischaemia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Headache
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Lung disorder
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Throat tightness
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Angioneurotic oedema
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Septal panniculitis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  60
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.2
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  30
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.3
</reportinggroupid>
<numevents>
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  90
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA 9.1
</sourcevocabulary>
<term>
  Aneurysm
</term>
</seriousevent>
</seriousadverseevents>
<sourcevocabulary>
</sourcevocabulary>
<timeframe>
</timeframe>
</reportedevents>
</clinical_result>
</clinical_study>
